We found that composition of cell subsets within the CD34 þ cell population is markedly altered in chronic phase (CP) chronic myeloid leukemia (CML). Specifically, proportions and absolute cell counts of common myeloid progenitors (CMP) and megakaryocyte-erythrocyte progenitors (MEP) are significantly greater in comparison to normal bone marrow whereas absolute numbers of hematopoietic stem cells (HSC) are equal. To understand the basis for this, we performed gene expression profiling (Affymetrix HU-133A 2.0) of the distinct CD34 þ cell subsets from six patients with CP CML and five healthy donors. Euclidean distance analysis revealed a remarkable transcriptional similarity between the CML patients' HSC and normal progenitors, especially CMP. CP CML HSC were transcriptionally more similar to their progeny than normal HSC to theirs, suggesting a more mature phenotype. Hence, the greatest differences between CP CML patients and normal donors were apparent in HSC including downregulation of genes encoding adhesion molecules, transcription factors, regulators of stem-cell fate and inhibitors of cell proliferation in CP CML. Impaired adhesive and migratory capacities were functionally corroborated by fibronectin detachment analysis and transwell assays, respectively. Based on our findings we propose a loss of quiescence of the CML HSC on detachment from the niche leading to expansion of myeloid progenitors.
Introduction
It has become widely accepted that activation of the BCR-ABL tyrosine kinase is causative for chronic myeloid leukemia (CML). 1 Still, involvement of additional molecular events in the pathogenesis of CML has been demonstrated. 2 For instance, in blast crisis (BC) CML elevated levels of b-catenin lead to expansion of the granulocyte-macrophage progenitor (GMP) subset, 2 and inactivation of the transcription factor JunB is able to increase the number of long-term hematopoietic stem cells (LT-HSC) and GMP in a murine model of myeloproliferative disease. 3 Previously, we examined CD34 þ stem and progenitor cells from patients with chronic phase (CP) CML by microarray technology. 4 The gene expression profile of the total CD34 þ cell population was suggestive for an altered composition of the CD34 þ compartment and flow cytometry-based CD34 þ cell subset analysis showed a greater proportion of megakaryocyteerythrocyte progenitors (MEP) whereas HSC and GMP subsets were proportionally decreased. These observations prompted us to perform a more detailed analysis of the molecular signature of CP CML using defined subsets rather than the total population of CD34 þ stem and progenitor cells. By gene expression profiling of CD34 þ subsets from the bone marrow (BM) of six patients with CP CML and five healthy donors, we shed some light on the transcriptional deregulation of the leukemic differentiation program. In addition, we provide evidence that the CML HSC has a transcriptionally more mature phenotype than its healthy counterpart, showing impaired adhesive and migratory capacities as well as decreased expression of prominent transcription factors and stem-cell regulators. Thus, we hypothesize that loss of HSC quiescence leads to expansion of mature progenitors in CP CML.
Patients and methods

Patients and cells
Informed consent was obtained according to a protocol approved by the ethics committee of Heinrich Heine University from all patients and donors included into this study. We obtained BM mononuclear cells from six patients with newly diagnosed Ph þ CP CML and five healthy BM donors. The two groups did not differ significantly with regard to age, gender and body weight. BM samples were processed within 2 h following puncture. CD34 þ cells were positively selected after density gradient centrifugation as previously described. 5 Immunofluorescence-based cell sorting LinÀ, CD34 þ , CD38À HSC and LinÀ, CD34 þ , CD38 þ myeloid progenitor subsets including IL-3Ra lo CD45RAÀ common myeloid progenitors (CMP), IL-3Ra lo CD45RA þ GMP and IL-3RaÀ, CD45RAÀ MEP were isolated from normal and CP CML CD34 þ BM cells by fluorescence-activated cell sorting as previously described. 6 Before the samples were subjected to gene expression analysis, we performed fluorescence in situ hybridization of the BCR-ABL fusion and quantitatively analyzed the BCR-ABL transcripts by reverse transcription (RT)-PCR (details of these analyses are presented in the Supplementary Figure 2) .
RNA isolation, amplification and hybridization to microarrays
A portion of 6 ng of total RNA was used for linear amplification with the Two Cycle Target Labeling Kit (Affymetrix UK Ltd, High Wycombe, UK) from highly purified LinÀ, CD34 þ , CD38À and LinÀ, CD34 þ , CD38 þ cell subsets. Then 10 mg cRNA were biotin-labeled using the Enzo BioArray HighYield RNA Transcript Labeling Kit (Affymetrix Ltd). Quality control of RNA and cRNA was performed using a bioanalyzer (Agilent 2001 Biosizing; Agilent Technologies, Waldbronn, Germany). Following fragmentation, labeled cRNA of each individual patient sample was hybridized to Affymetrix U133 2.0 GeneChips covering 14 500 genes and stained according to the manufacturer's instructions. Our gene expression analyses fulfilled the recently published consensus guidelines from three European leukemia networks. 7 Array data have been stored in the gene expression omnibus database (www.ncbi.nlm.nih.gov/geo/; accession no.: GSE11889) according to MIAME standards.
Quantification, normalization and statistical analysis of gene expression data Analysis of differences between distinct subsets. Array data were analyzed using dChip. 8 For normalization, the smoothing spline algorithm was performed and expression values were calculated by applying the perfect match-mismatch difference model algorithm. 8 We considered a gene differentially expressed if the transcript level as a multiple of the control was 41.5 or o1.5, the lower confidence bound (LCB) 41.2 or o1.2 and the P value o0.1. The LCB is a stringent estimate of the change in expression as a multiple of the control and has been shown to be a superior ranking statistic. 9 The use of LCB provides a 90% confidence that the actual change in expression as a multiple of the control is a value above the reported LCB. To check differential expression of genes identified by linear amplification and array analysis, we analyzed six genes which were differentially expressed in normal versus CP CML HSC by quantitative RT-PCR (qRT-PCR). We confirmed the results of the array analysis in all cases and found that the extent of differential expression measured by qRT-PCR was in five out of six cases greater than measured by the microarrays (Supplementary Figure 2) .
Pathway analysis. For pathway analysis, data were normalized using the variance stabilizing method 10 and summarized using median polish. To identify differential expression between CD34 þ cell subsets, the rank product test was used. 11 The rank product test is a nonparametric test, which is particularly applicable for small sample sizes and deviation from assumed underlying probability distributions in microarray analyses. 12 Genes were considered to be regulated between two cell subsets if the rank product showed a false-positive rate below 0.05. Genes above this threshold were considered to be not regulated. Genes that were indicated as significantly regulated by the rank product test were subsequently used to extract pathways from the Biocarta database available online at the NCI website (http:// pid.nci.nih.gov/browse_pathways.shtml#biocarta). To determine the relevance of the resulting pathways the Globaltest 13 was performed. Significance was determined by using Cochran's Q test. 13 The significance value associated with the Globaltest results is a measure for how well the group of genes as a whole can distinguish between the conditions under study. Statistical and numerical analysis was performed in the R statistical programming environment using the Bioconductor toolset (http://www.bioconductor.org). Database queries and restructuring were done using custom scripts in the PERL scripting language.
Distance Analysis. Unsupervised clustering was performed on the geometric sample means of the respective CD34 þ cell subset (HSC, CMP, GMP, MEP) array sets using complete linkage hierarchical clustering with the Euclidean distance between CD34 þ cell subset array sets as distance metric. Three clusterings were done, one using the combined set of healthy and CML cell subset arrays and two for the separate sets (healthy and CML, respectively) and the results were presented in a tree diagram.
Quantitative real-time reverse transcription polymerase chain reaction Corroboration of RNA expression data was performed by realtime RT-PCR using the Light Cycler 1.2 (Roche, Mannheim, Germany) as described before. 4 GAPDH mRNA served as control for relative quantification. Relative gene expression levels are presented as the difference of C T values of the target gene and GAPDH (DDC T ). A list of genes that were confirmed with qRT-PCR together with the respective primer sequences is provided in the Supplementary Table 1.
In vitro adhesion and migration analysis
For adhesion analysis, purified LinÀ, CD34 þ , CD38À HSC (0.5 Â 10 4 ) were plated on fibronectin-coated dishes (BD Biosciences, Heidelberg, Germany) in fully supplemented Iscove's medium as described.
14 Cultures were incubated for 3 h at 37 1C under 5% CO 2 in a humidified atmosphere. Nonadherent cells were removed by five washes with phosphate-buffered saline, after which adherent cells were quantified by light microscopy.
Chemotaxis assays were performed using a transwell with a pore size of 5 mm (Corning-Costar Corp., Corning Incorporated Life Sciences, Lowell, MA, USA). Purified LinÀ, CD34 þ , CD38À cells (5 Â 10 4 ) in fully supplemented Iscove's medium were added to the upper well. Chemotaxis toward 100 ng/ml murine stromal-derived factor 1 (SDF-1; R&D Systems, Wiesbaden-Nordenstadt, Germany) in the lower chamber was allowed to continue for 4 h at 37 1C under 5% CO 2 in a humidified atmosphere. Cells were harvested from the lower well and stained with a fluorescein isothiocyanate-conjugated (FITC) monoclonal anti-CD34 antibody (clone 8G12, BD Biosciences, Heidelberg, Germany). For standardized cell counting 20 000 calibration beads were added to the cell suspension. The cell suspension was analyzed using a flow cytometer until 10 000 calibration beads were counted. The number of CD34 þ cells was then multiplied by factor 2 and shows the absolute number of migrated CD34 þ cells. Based on the number of cells added to the assay the proportion of migrated cells was determined. Student's t-test was used to assess significant differences regarding adhesion and cell migration between CML patients and healthy donors.
Results and discussion
Common myeloid and megakaryocyte-erythrocyte progenitors are expanded in the bone marrow of CP CML In CML samples, the proportion of primitive HSC within the CD34 þ stem and progenitor cell population was significantly smaller (P ¼ 0.0003) with a mean of 2.7% (s.d. Figures 1a and b) . The data reflect an expansion of myeloid progenitors in CP CML emerging from a HSC population with a quantity alike in normal donors.
Gene expression analysis of CML CD34 þ cell subsets
Based on the gene expression profiles of the distinct CD34 þ subsets in six patients with CML and five normal donors, we looked at the transcriptional regulation of the differentiation processes from HSC along the line of differentiation in CML patients and normal individuals, separately. Then, we compared the distinct CML subsets with their normal counterparts, to get a better insight into the transcriptional differences in HSC, CMP, GMP and MEP. Results of these analyses are detailed below.
Lineage differentiation shows similarities of the CML HSC with more mature progenitors
Looking at the differentiation process we found 178 and 701 genes differentially regulated from HSC to CMP in CML patients and normal donors, respectively. The differences observed between CML patients and normal donors during differentiation from CMP to MEP or GMP were modest, reflecting the lack of a differentiation block in CP CML. 15 Analyzing the overlap of genes regulated during transition from HSC to CMP in CML patients and normal donors, we found only six genes concordantly regulated (Supplementary Figure 3) . A pathway analysis of the differentially expressed genes showed a significant regulation of cell differentiation related genes during transition from HSC to CMP only in normal donors (27/572 annotated genes, P ¼ 0.006283) and not in CML patients. In a crosswise analysis we compared the HSC subset of patients with CML and the CMP subset of normal donors and found 325 differentially expressed genes. These were 56% fewer genes than observed between the HSC and CMP subsets in normal hematopoiesis. Although differences between the distinct subsets seemed to be generally moderate with regard to the absolute numbers of differentially expressed genes, our findings suggest a particular similarity of the transcriptomes of the CML HSC and normal CMP (Figure 2a) . To further corroborate this observation, we performed Euclidian distance analysis of the whole unselected datasets. This analysis confirmed our assumption, as a close proximity of all CML subsets became apparent (Figure 2b) . Notably, looking at the CD34 þ cell subsets from CML patients and healthy donors together, all subsets from patients, including the HSC, cluster around the CMP of healthy donors, suggesting a more mature transcriptional phenotype of HSC in CML patients. In contrast, for normal individuals, the cluster tree clearly resembled the model for hierarchical development from the HSC to mature cells with the HSC sitting at the top of the hierarchy and the more differentiated MEP and GMP subsets at the bottom as proposed by Manz et al. 6 All together, the transcriptome of CML patients and healthy individuals apparently differed mainly at the level of HSC and not at later progenitor stages providing further evidence for the HSC origin of CML and its addiction to oncogenic events stimulated by BCR-ABL. 16, 17 We determined these differences in more detail and found a total of 614 genes differentially expressed between CML patients' and normal donors' HSC including 362 genes with a lower expression level and 252 genes with a higher one, respectively (Supplementary Table 2 ). Based on these observations and the detailed molecular profile of the CML HSC, we suggest in the following a scheme of malignant transformation in CP CML.
The HSC subset of patients with CML shows impaired migratory and adhesive properties
In the HSC of patients with CML the gene expression level of the chemokine receptor CXCR4 and the adhesion molecules L-selectin, CD44 and N-cadherin (CDH2) was significantly lower as compared to normal donors. This is in line with previous reports showing that the BCR-ABL oncogene caused downregulation of L-selectin and CXCR4 in hematopoietic cells. [18] [19] [20] We also found decreased expression levels of genes encoding for members of the CXCR4 downstream signaling pathway in CML HSC including phosphoinositol-3-kinase (PI3K) 21 ,22 and 3-phosphoinositide-dependent protein kinase-1 (PDK1) 22 as well as atypical protein kinase C (aPKC). [22] [23] [24] With regard to cell migration and chemotaxis, genes encoding for hematopoietic cell-specific DOCK2, 25 PDE4, 26 and PTP4A1 27 were downregulated in CML HSC (Table 1) . These results were strengthened by a BioCarta-based pathway analysis showing differential regulation of the pathways cell to cell adhesion signaling, CXCR4 signaling pathway and role of PI3K subunit p85 in actin organization and cell migration in the HSC of CML patients compared to healthy donors ( Figure 3 ). To functionally corroborate these findings, we assessed adhesion and transmigration using in vitro assays and found a significantly reduced proportion of adhesive and migrating HSC in CML patients compared to their normal counterparts. The relative adhesion of CML HSC compared to HSC from healthy donors to the fibronectin-coated dish was reduced to 65.8% (mean, range 50.5-81.7% P ¼ 0.02; Figure 4a ). Regarding the migratory capacities we found that 4.1% (mean; range 1.4-9.6%) of the HSC subset from patients with CML vs 14.8% (mean; range 6.6-22.2%; P ¼ 0.01) of the respective cells from healthy donors migrated through the transwell chamber (Figure 4b ). Clustering was performed on the geometric sample means of the respective CD34 þ cell subsets using complete linkage hierarchical clustering with the Euclidean distance between celltypes as distance metric. Figure 2) . SRC  CTNNA1  ACTA1  CTNNB1  VCL  CSK  FAK  PXN  SHP-2   PAK1  CDC42  ARP2  ARP3  ARPC1A  ARPC1B  ARPC2  ARPC3  ARPC4  WASP  PDGFA  PDGFR  PIK3CA  PIK3R1  RHO We therefore hypothesize that impaired adhesive and migratory capacities lead to detachment from and hinder migration to the stem-cell niche. Thus, deprived of their natural habitat, HSC lose quiescence on disruption of the receptor interaction with ligands provided by the niche-building tissues as shown for CXCR4 and SDF-1. 28, 29 Interestingly, binding of SDF-1 to CXCR4 increases the activity of the transcription factors JunB 30 and c-Fos, 31 which we both found downregulated in HSC of CML patients. Therefore, loss of stem-cell quiescence on disruption of the ligand-receptor interaction might be mediated by downregulation of transcription factors.
The HSC subset of patients with CP CML shows lower gene expression levels of transcription factors and genes promoting stem-cell self-renewal Accordingly, we observed a reduced transcriptional activity of transcription factors and transcriptional regulators in the HSC subset of CML patients (Table 1) . Among them were the activating protein-1 family member c-fos and the nuclear receptor subfamily 4A members 2 and 3 (NR4A2 and A3), kruppel-like factor family members 2 and 11, C/EBP-b and myeloid zink finger 1 (MZF1). As NR4A3 and NR4A1 have recently been identified as potential upstream regulators of c-Jun and JunB in a murine AML model, 32 we performed qRT-PCR to examine the expression levels of NR4A1 and to confirm downregulation of NR4A3. We detected a significant downregulation of NR4A1 and NR4A3 in HSC of CML patients by RT-PCR (Supplementary Figure 2) . Of note, NR4A1 and NR4A3 knockout mice showed expansion of myeloid progenitors, but not HSC resembling more the hematopoietic phenotype of CML than AML. This observation is in accordance with our quantitative subsets analysis in CP CML patients. Overall, the decreased gene expression of three NR4A family members suggests an important role in stem-cell quiescence. In line, we also found decreased transcriptional activity of molecules involved in the maintenance of stem-cell fate such as FLT3 and PTEN (Table 1) . Inhibition of FLT3 led to a reduction of the stem-cell pool 33 and inactivation of PTEN caused long-term decline of HSC fostering differentiation and proliferation 34 in murine models. Accordingly, gene expression levels of CD133 were lower in CML HSC compared their normal counterparts. Low expression of CD133 glycoprotein is associated with a more mature, proliferative cell fraction. 35 We also found a decreased expression of the genes encoding for L-selectin and CD53 in the HSC subset of CML patients (Table 1) . These molecules seem to segregate asymmetrically in HSC according to the model of asymmetric cell division and characterize daughter cells that maintain stem-cell fate. 36 Hence, lower expression suggests perturbance of the hematopoietic homeostasis that might lead to a greater proportion of differentiating cells than actually needed to replenish the peripheral blood. In summary, these transcriptional changes suggest a loss of quiescence in the CML HSC leading to an increased proliferative activity and expansion of the myeloid progenitors. In accordance with this, we found decreased expression levels of genes associated with the inhibition of cell-cycle progression (Table 1) . Among them was member 3 of the membrane-spanning 4-domains subfamily A, 37 that is able to suppress S-phase entry, as well as Ran/TC4 that causes cell-cycle arrest in G2-phase 38 and prolongs the duration of the S-phase. 39 Considering our findings and the reexpression of adhesion molecules as CXCR4 in CML stem and progenitor cells following tyrosine kinase inhibitor (TKI) therapy, 18, 40, 41 an eradication of the Ph þ clone could be based on therapeutic principles antagonizing receptor-ligand interactions such as CXCR4 and SDF-1. This may be achieved administering the CXCR4 antagonist Plerixafor (AMD 3100) 29, 42 or by enzymatic cleavage following granulocyte colony-stimulating factor (G-CSF) therapy 43, 44 in combination with TKI. Furthermore, the phenotype of the CML HSC revealed by our analysis suggests a high susceptibility to cytotoxic chemotherapy. This might explain the achievement of long-term remissions after high-dose therapy followed by syngeneic BM transplantation in CP CML. 45 
Conclusion
Taken together, our findings help to explain that the myeloid CD34 þ subsets expand in CP CML whereas the cell counts of the more primitive HSC subset equal those of normal donors. The BCR-ABL driven expansion of the myeloid subsets appears to originate from the HSC, which is unable to enter quiescence. This results in a continuous replenishment of the progenitor pools. As the progenitors in CP CML do not have a differentiation block, as reflected by the transcriptional similarity of CML progenitors and their normal counterparts, their expansion leads to an accumulation of maturating white blood cells. The changes in the HSC, including downregulation of genes involved in the regulation of adhesion and cell motility, stemcell self-renewal, differentiation and inhibition of proliferation are associated with a transcriptional phenotype resembling that of normal CMP without losing the immunophenotype of HSC. This could also be of relevance for future therapies as TKI treatment leads to a reconstitution of adhesion and quiescence in the CML stem cell. Eradication of the Ph þ clone could therefore be based on therapeutic principles antagonizing receptor-ligand interactions such as CXCR4 and SDF-1, that is, by blockage of CXCR4 or enzymatic cleavage following administration of G-CSF in combination with TKI.
